EU Cosmetics Animal Testing Ban vs. China Market Entry: The Compliance Dilemma European Brands Aren't Prepared For

The email arrives from a distributor in Shanghai. It’s a routine pre-launch checklist — until item seven: animal toxicology reports, required by China’s NMPA for imported special-use cosmetics. The brand’s regulatory manager reads it twice. Their hero product is a high-SPF moisturizer, which places it squarely in China’s “special use” category. Animal tests are required.

The problem is immediate and structural. Under EU Regulation (EC) No 1223/2009, generating new animal safety data for a cosmetic product — anywhere in the world, for cosmetics purposes — makes that product unsellable in Europe. The brand has just discovered, three months before launch, that its China strategy and its EU compliance status are in direct conflict.

This scenario plays out more often than you’d expect across Europe’s over-€80-billion cosmetics sector. Sunscreens, whitening serums, hair dyes, anti-hair-loss treatments — the product categories most likely to carry a premium price point in China are disproportionately likely to carry an animal testing requirement there too. Understanding exactly what EU Regulation 1223/2009 prohibits, what China’s 2021 reforms actually changed, and where the legitimate compliance pathways lie is now essential knowledge for any European brand with export ambitions in Asia.

What Article 18 of Regulation (EC) No 1223/2009 Actually Prohibits

Article 18 is the operative provision. Since March 11, 2013 — the date the final marketing ban came into full force — the prohibition runs in two parallel tracks.

Track one bans placing on the EU market any cosmetic product whose finished formulation was tested on animals. Track two bans placing on the EU market any cosmetic product containing ingredients or combinations of ingredients tested on animals “for the purposes of this Regulation.”

The phrase “for the purposes of this Regulation” carries significant legal weight. The ban doesn’t prohibit cosmetics companies from referencing animal data — it prohibits them from using animal data generated specifically to satisfy cosmetics safety requirements. This distinction creates one legitimate source of animal data that remains accessible: REACH chemical registrations. Under REACH (Regulation (EC) No 1907/2006), ingredient manufacturers register industrial chemicals with full toxicological dossiers that often include animal study data. Cosmetics formulators can use that pre-existing REACH data in their safety assessments because the testing was conducted for industrial chemical compliance, not for cosmetics purposes. The Scientific Committee on Consumer Safety (SCCS) explicitly endorses this approach in its published Notes of Guidance for the Testing of Cosmetic Ingredients and their Safety Evaluation.

What the ban does catch — firmly and extraterritorially — is any new animal testing commissioned to demonstrate the safety of a cosmetic ingredient or finished product, regardless of whether the testing is conducted in a Paris suburb or a certified facility in Guangdong. The location of the lab is irrelevant. The purpose of the testing is what triggers the prohibition.

And that extraterritorial reach is precisely what creates the conflict with Chinese requirements.

China’s 2021 Reform — Partial Relief, Not a Full Solution

China’s Cosmetics Supervision and Administration Regulation (CSAR), which took effect January 1, 2021, replaced rules that dated back to 1989. It brought genuine and meaningful reform to animal testing requirements for imported cosmetics — but it’s a partial reform, and overstating its scope has already caused problems for European brands that assumed it resolved the conflict entirely.

For ordinary cosmetics (普通化妆品) — products with no special claims — the reform opened a viable non-animal pathway. Brands can now submit a safety self-assessment drawing on published safety data, existing OECD-validated in vitro results, and structured risk assessments, provided the formulation uses only ingredients listed in the IECIC (China’s Inventory of Existing Cosmetic Ingredients in China, 2021 edition, which contains over 8,900 substances). For a straightforward moisturizer or cleanser built from well-documented ingredients, this is genuinely workable and broadly compatible with EU Regulation 1223/2009’s non-animal evidence standards.

For special-use cosmetics (特殊化妆品), the picture is fundamentally different. As of 2026, at least six product categories continue to require animal testing under NMPA rules for imported products:

• Sunscreen products (any SPF claim, regardless of level)
• Hair-dyeing products
• Perming and hair-straightening products
• Anti-hair-loss products
• Freckle-removing and skin-whitening products
• Novel categories making new or unrecognized claims

These aren’t niche product types. For many European premium cosmetics brands, 2 or more of these categories sit at the core of their commercial range. A French dermo-cosmetics label built around SPF moisturizers and brightening serums is unlikely to escape the special-use classification — and with it, the animal testing requirement.

China’s 2021 reform narrowed the conflict significantly for brands operating in the ordinary cosmetics space. For brands in the special-use segment, it left the fundamental tension intact.

The Dual-Track Strategy: Maintaining EU Compliance While Accessing China

The approach used by European brands that successfully navigate both markets is not a regulatory workaround. It’s a deliberate product architecture decision that treats the EU and Chinese markets as distinct regulatory environments — which, legally, they are.

The EU-registered version is documented entirely under Regulation (EC) No 1223/2009. Its Cosmetic Product Safety Report (CPSR), prepared by a qualified safety assessor, contains no animal data generated for cosmetics purposes. Safety is demonstrated through validated in vitro methods: skin sensitization via the h-CLAT or KeratinoSens assay (OECD TG 442C/D/E), skin and eye irritation via reconstructed human epidermis models (OECD TG 439 and TG 492), phototoxicity via the 3T3 NRU test (OECD TG 432), and supported by existing human data and published toxicological reviews. The EU responsible person (as defined under Article 4 of Regulation 1223/2009) maintains the product information file in the EU, typically accessible to national authorities such as France’s ANSM or the DGCCRF.

The China-registered version is a separate regulatory entity. It may share the same formulation, but it’s registered in China through a formally designated China-responsible agent — the 备案人 (filing party) for ordinary cosmetics or the 注册人 (registrant) for special-use products. Any animal testing required by NMPA is conducted by Chinese-authorized laboratories operating under NMPA oversight. This testing serves Chinese regulatory compliance. It does not appear in the EU CPSR. It is not used to support EU safety claims.

The legal architecture holds as long as these two tracks remain genuinely separate. The EU-registered product is not marketed in China without its own Chinese registration. The China-registered version — if it carries animal test data in its NMPA dossier — is not placed on the EU market.

This isn’t a technicality. It’s the structural logic that makes dual-market participation legally defensible under both regulatory frameworks simultaneously.

What Your Documentation Must Reflect — and Where Brands Go Wrong

The documentation requirements for a clean dual-track setup are specific. Getting the architecture right at the start saves months of rework at the worst possible moment.

Your EU CPSR must reference safety data from clearly non-cosmetics sources: REACH registration dossiers, ECHA-published chemical safety reports, SCCS scientific opinions on specific ingredients, peer-reviewed toxicology literature. Any data source that could be characterized as animal testing commissioned for cosmetics purposes — even indirectly — compromises the EU filing.

Your NMPA-facing dossier operates under entirely separate evidentiary rules and is compiled by your China-responsible agent using NMPA-approved data sources. It must not be treated as interchangeable with the EU CPSR.

Two documentation mistakes account for most of the compliance failures we see among European brands entering both markets:

Mistake one: commissioning a single “global” safety study that includes animal-testing components, then trying to use it across both filings. This collapses the dual-track structure immediately. The EU CPSR is contaminated by the animal data reference, and the brand faces a choice between withdrawing the EU product or abandoning China market access.

Mistake two: reformulating for China and not re-registering in the EU. If the China version uses a different concentration of a UV filter, or substitutes one preservative for another to meet IECIC requirements, it may no longer match the EU-registered formula. That version cannot be placed on the EU market under the existing EU registration. Brands that ship “close enough” reformulations across markets expose themselves to enforcement action on both sides.

The Decision Point Is Earlier Than Most Brands Realize

The European brands that navigate this most successfully share one practice: they conduct the regulatory pathway analysis at the formulation stage, not after the product brief is finalized.

If an SPF moisturizer is destined for both EU and Chinese markets, the decision about whether to pursue dual-track registration (with separate animal-tested Chinese SKUs), reformulate the EU product to fall outside China’s special-use classification, or prioritize one market over the other should happen when the formula is still fluid. Reformulating to remove an SPF claim costs almost nothing at the brief stage. It can cost months and €30,000–€60,000 in re-registration fees and shelf-stock write-offs after launch.

The same logic applies to whitening claims — a category where the EU’s restrictive approach to active ingredient concentrations (e.g., the prohibition on certain kojic acid concentrations under Annex II of Regulation 1223/2009) often intersects with Chinese classification thresholds in ways that aren’t obvious until a specialist maps them.

The EU-China compliance problem isn’t really a testing problem. It’s a dossier architecture problem — and most brands discover that far too late in the product development cycle. Getting the architecture right, built on accurate regulatory mapping of both frameworks from the outset, is what separates a clean dual-market launch from an expensive mid-launch renegotiation.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry and dual-market compliance strategy. Contact us

Related from our network

• Non-Animal Safety Testing for Cosmetics Entering the US Market — Qalitex Laboratories provides ISO 17025-accredited in vitro testing for European cosmetics brands pursuing FDA-compliant US distribution, using validated methods recognized under both EU and US frameworks.
• Canadian NHPD and GMP Compliance for European Cosmetic Brands — Androxa guides European brands through Health Canada’s Natural Health Products Directorate requirements, including GMP audits and registration support for the Canadian market.